Dr Uzma Zaidi 
(Karachi, Pakistan)

‘I thank iCMLf for providing me the opportunity to participate in the 18th John Goldman Conference. I got a chance to listen to international experts, to see what approaches they are following and how they are managing their patients. This meeting has greatly enhanced my knowledge on CML and given me so many new ideas to better help my patients in home town, both from the diagnostic and the management point of view’.
(Dr Zaidi, Pakistan) 

Uzma Zaidi was supported by the iCMLf Goldman Fund to attend the John Goldman Conference on CML in Houston in 2016. She also undertook a 4-week clinical preceptorship at the MD Anderson Cancer Center in Houston directly after her attendance at the meeting. 

‘The main issue in Pakistan is to get access to regular monitoring for my patients. 
I am hoping to learn some diagnostic techniques during the preceptorship and to improve my skills and knowledge in terms of diagnosis and biology of CML. This will help me to find solutions for my patients’. 
(Dr Zaidi in advance of her preceptorship)

Current position and educational background:

Dr Zaidi is the Bone Marrow Transplant Coordinator, Head of the Section of Myeloproliferative Neoplasms, Assistant Professor & Consultant Hematologist at the National Institute of Blood Diseases & Bone Marrow Transplantation in Karachi (Pakistan). She is also the Co-investigator of MERGE study, the Global MPN Registry. She is also Director Laboratory at Darul Sehat Hospital in Karachi.

Dr Zaidi completed her training in hematology (FCPS Program) under supervision of Dr Tahir Shamsi at the National Institute of Blood Disease & Bone Marrow Transplantation in Karachi, Pakistan. 

Current research interests:

• Coexistence of PDGFRB mutation & Deletion 5q in a patient with hypereosinophilia. (poster presentation, 2016 at International MPN conference, Estoril, Portugal)
• Molecular analysis & identification of genetic polymorphisms in triple negative ET patient. (poster presentation, 2016 at International MPN conference, Estoril, Portugal)
• Disease spectrum and clinical outcome of patients with Philadelphia negative myeloproliferative neoplasms: a single centre experience (poster presentation, 2016 at International MPN conference, Estoril, Portugal)
• Hematological and molecular responses to nilotinib as frontline therapy in   newly diagnosed CML patients (paper presentation, 2015)
• Red cell alloimmunization in regularly transfused Beta Thalassemia patients (publication, 2015)

{rscomments off}